<DOC>
	<DOCNO>NCT02885012</DOCNO>
	<brief_summary>The purpose study learn safety effect switch treatment bosentan ( Tracleer ) macientan ( Opsumit ) ambrisentan ( Letairis ) 24 week subject Connective Tissue Disease associate Pulmonary Arterial Hypertension ( CTD-PAH ) .</brief_summary>
	<brief_title>Crossover Study From Macitentan Bosentan Over Ambrisentan</brief_title>
	<detailed_description>The study consist group subject bosentan least three month group macitentan least three month . Both group switch Letairis 5mg daily bosentan macitentan therapy three month increase dose Letairis 10mg daily week 4 well tolerate .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Diagnosis Connective Tissue Disease ( CTD ) Age range : 1880 year old Previous Right Heart Catheterization ( RHC ) demonstrate PAH Forced vital capacity ( FVC ) great 50 % Carbon Monoxide Diffusing Capacity ( DLCO ) great 50 % World Health Organization ( WHO ) functional class II III Able perform 6 minute walk test ( 6MWT ) Stable dose antihypertensive medication Nonpregnant female Have currently stable dose bosentan least 3 month Adequate acoustic image allow transthoracic echocardiography perform Exercise limitation relate noncardiopulmonary reason ( e.g . arthritis ) Severe systemic hypertension great 170/95 Patients prior history cardiovascular disease WHO functional class IV status Patients severe organ disease felt investigator impact survival course study . FVC le 50 % predict DLCO le 50 % predict</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>